Linical Co Ltd
TSE:2183
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Linical Co Ltd
Cash & Cash Equivalents
Linical Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Linical Co Ltd
TSE:2183
|
Cash & Cash Equivalents
¥5.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
2%
|
CAGR 10-Years
6%
|
|
|
Carna Biosciences Inc
TSE:4572
|
Cash & Cash Equivalents
¥516.8m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-11%
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Cash & Cash Equivalents
¥15.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
19%
|
CAGR 10-Years
14%
|
|
|
Medinet Co Ltd
TSE:2370
|
Cash & Cash Equivalents
¥1.9B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-2%
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Cash & Cash Equivalents
¥893.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
|
D
|
DNA Chip Research Inc
TSE:2397
|
Cash & Cash Equivalents
¥410.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-6%
|
|
Linical Co Ltd
Glance View
Linical Co., Ltd. engages in pharmaceutical contract research projects providing consulting, monitoring, and quality control services to pharmaceutical companies. The company is headquartered in Osaka, Osaka-Fu and currently employs 845 full-time employees. The company went IPO on 2008-10-27. The firm operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
See Also
What is Linical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
5.2B
JPY
Based on the financial report for Dec 31, 2025, Linical Co Ltd's Cash & Cash Equivalents amounts to 5.2B JPY.
What is Linical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
6%
Over the last year, the Cash & Cash Equivalents growth was -24%. The average annual Cash & Cash Equivalents growth rates for Linical Co Ltd have been -9% over the past three years , 2% over the past five years , and 6% over the past ten years .
